Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313025 | 0.84 | CHRNB2 (0.37) | CHRNB2CHRNA4HTR2CSLC6A2SLC6A4 | |
| SCHEMBL3317620 | 0.84 | ADRB2 (0.41) | ADRB2SOS1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3319177 | 0.76 | SOS1 (0.37) | SOS1OPRL1 | |
| SCHEMBL3314991 | 0.76 | ADRB2 (0.54) | ADRB2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24007286 | 0.72 | SOS1 (0.36) | SOS1SLC6A4HTR2A | |
| SCHEMBL9900783 | 0.71 | LMNA (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C | |
| SCHEMBL3317547 | 0.70 | HTR6 (0.45) | ADRB2SSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL84044 | 0.68 | ALDH1A1 (0.41) | SLC6A2 | |
| SCHEMBL3316512 | 0.68 | DRD2 (0.38) | CHRNB2CHRNA4SSTR4SLC6A2SLC6A4 | |
| SCHEMBL3316680 | 0.67 | CNR1 (0.40) | SOS1CHRNB2CHRNA4HTR2CSSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | ADRB2 43/4885SOS1 521/4885CHRNB2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.